Leukemia & Lymphoma, Volume 61, Issue 2 (2020)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Leukemia & Lymphoma, Volume 61, Issue 2 (2020)

See all volumes and issues
Vol 65, 2024 Vol 64, 2023 Vol 63, 2022 Vol 62, 2021 Volume 61, 2020 Vol 60, 2019 Vol 59, 2018 Vol 58, 2017 Vol 57, 2016 Vol 56, 2015 Vol 55, 2014 Vol 54, 2013 Vol 53, 2012 Vol 52, 2011 Vol 51, 2010 Vol 50, 2009 Vol 49, 2008 Vol 48, 2007 Vol 47, 2006 Vol 46, 2005 Vol 45, 2004 Vol 44, 2003 Vol 43, 2002 Vol 42, 2001 Vol 41, 2001 Vol 40, 2000-2001 Vol 39, 2000 Vol 38, 2000 Vol 37, 2000 Vol 36, 1999-2000 Vol 35, 1999 Vol 34, 1999 Vol 33, 1999 Vol 32, 1998-1999 Vol 31, 1998 Vol 30, 1998 Vol 29, 1998 Vol 28, 1997-1998 Vol 27, 1997 Vol 26, 1997 Vol 25, 1997 Vol 24, 1996-1997 Vol 23, 1996 Vol 22, 1996 Vol 21, 1996 Vol 20, 1995-1996 Vol 19, 1995 Vol 18, 1995 Vol 17, 1995 Vol 16, 1995 Vol 15, 1995 Vol 16, 1995 Vol 15, 1995 Vol 14, 1994 Vol 13, 1994 Vol 12, 1993-1994 Vol 11, 1993 Vol 10, 1993 Vol 9, 1993 Vol 8, 1992 Vol 7, 1992 Vol 6, 1991-1992 Vol 5, 1991 Vol 4, 1991 Vol 3, 1990-1991 Vol 2, 1990 Vol 1, 1989-1990
Download citations Download PDFs

Commentaries

Article Commentary
PET positivity – the agony of choice: response assessment and interpretation of increased FDG uptake of residual mediastinal tissue after frontline therapy in Hodgkin lymphoma
Sarah Gillessen, Carsten Kobe, Andreas Engert & Bastian von Tresckow
Pages: 251-254
Published online: 16 Jan 2020
First Page PreviewforPET positivity – the agony of choice: response assessment and interpretation of increased FDG uptake of residual mediastinal tissue after frontline therapy in Hodgkin lymphoma | Full Text | References | PDF (365.8 KB) | EPUB
  • 133 Views
  • 2 CrossRef citations
  • 0Altmetric
Article Commentary
Activation-induced T-cell exhaustion: too much of a good thing?
Stephen M. Ansell
Pages: 255-256
Published online: 17 Dec 2019
CitationforActivation-induced T-cell exhaustion: too much of a good thing? | Full Text | References | PDF (239.6 KB) | EPUB
  • 113 Views
  • 0 CrossRef citations
  • 0Altmetric

Reviews

Review
Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease
Piers Blombery
Pages: 257-262
Published online: 18 Sep 2019
AbstractforMechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease | Full Text | References | PDF (509.2 KB) | EPUB
  • 749 Views
  • 13 CrossRef citations
  • 0Altmetric
Review
Methyltransferase DNMT3B in leukemia
Haibin Zhang, Houqun Ying & Xiaozhong Wang
Pages: 263-273
Published online: 24 Sep 2019
AbstractforMethyltransferase DNMT3B in leukemia | Full Text | References | PDF (1.3 MB) | EPUB
  • 453 Views
  • 5 CrossRef citations
  • 0Altmetric

Original Article

Article
Primary immunodeficiencies and lymphoma: a systematic review of literature
Mathilde Herber, Philippe Mertz, Yannick Dieudonné, Blandine Guffroy, Sophie Jung, Vincent Gies, Anne-Sophie Korganow & Aurélien Guffroy
Pages: 274-284
Published online: 03 Oct 2019
AbstractforPrimary immunodeficiencies and lymphoma: a systematic review of literature | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
  • 857 Views
  • 16 CrossRef citations
  • 0Altmetric

Letter to the Editor

Letter
Report of the International Splenic Lymphoma Study Group meeting held in 2019 in Barcelona, Spain
Maria Joao Baptista, Francesc Sole, Aaron Polliack & Estella Matutes
Pages: 285-287
Published online: 15 Oct 2019
First Page PreviewforReport of the International Splenic Lymphoma Study Group meeting held in 2019 in Barcelona, Spain | Full Text | PDF (454.8 KB) | EPUB | Supplemental
  • 80 Views
  • 0 CrossRef citations
  • 0Altmetric

Emerging Drug Profile

Review
CPX-351 (vyxeos) in AML
Mansour Alfayez, Hagop Kantarjian, Tapan Kadia, Farhad Ravandi-Kashani & Naval Daver
Pages: 288-297
Published online: 24 Sep 2019
AbstractforCPX-351 (vyxeos) in AML | Full Text | References | PDF (749.8 KB) | EPUB
  • 2710 Views
  • 52 CrossRef citations
  • 0Altmetric

Original Articles

Article
Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era
Kekoa Taparra, Heshan Liu, Mei-Yin Polley, Kay Ristow, Thomas M. Habermann & Stephen M. Ansell
Pages: 298-308
Published online: 13 Sep 2019
AbstractforBleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era | Full Text | References | PDF (1.3 MB) | EPUB | Supplemental
  • 493 Views
  • 11 CrossRef citations
  • 0Altmetric
Article
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies
Tanya Siddiqi, Paul Frankel, Jan H. Beumer, Brian F. Kiesel, Susan Christner, Chris Ruel, Joo Y. Song, Robert Chen, Kevin R. Kelly, Sikander Ailawadhi, Paul Kaesberg, Leslie Popplewell, Sandrine Puverel, Richard Piekarz, Stephen J. Forman & Edward M. Newman
Pages: 309-317
Published online: 16 Oct 2019
AbstractforPhase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies | Full Text | References | PDF (1.3 MB) | EPUB | Supplemental
  • 2761 Views
  • 21 CrossRef citations
  • 0Altmetric
Article
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
Mattia Novo, Grzegorz S. Nowakowski, Thomas M. Habermann, Thomas E. Witzig, Ivana N. Micallef, Patrick B. Johnston, David J. Inwards, Barbara Botto, Kay M. Ristow, Jason R. Young, Umberto Vitolo & Stephen M. Ansell
Pages: 318-327
Published online: 26 Sep 2019
AbstractforPersistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe? | Full Text | References | PDF (1.5 MB) | EPUB | Supplemental
  • 303 Views
  • 8 CrossRef citations
  • 0Altmetric
Article
De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era
Bei Hu, Loretta J. Nastoupil, Sanam Loghavi, Jason R. Westin, Beenu Thakral, Luis E. Fayad, Fredrick Hagemeister, Sattva Neelapu, Felipe Samaniego, Hun J. Lee, Michael L. Wang, Michelle Fanale, Nathan Fowler & Yasuhiro Oki
Pages: 328-336
Published online: 18 Sep 2019
AbstractforDe novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
  • 401 Views
  • 7 CrossRef citations
  • 0Altmetric
Article
Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study
Liqiang Wei, Jingwen Wang, Jin Ye, Lei Yang, Jia Cong, Xin Li, Yiping Wu, Xueying Cui, Jing Ding, Na Yao & Jing Yang
Pages: 337-343
Published online: 13 Sep 2019
AbstractforLong-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study | Full Text | References | PDF (884.1 KB) | EPUB
  • 148 Views
  • 6 CrossRef citations
  • 0Altmetric
Article
Prognostic factors in pediatric Hodgkin lymphoma: experience from a developing country
Tariq Ghafoor
Pages: 344-350
Published online: 19 Sep 2019
AbstractforPrognostic factors in pediatric Hodgkin lymphoma: experience from a developing country | Full Text | References | PDF (658.7 KB) | EPUB
  • 260 Views
  • 6 CrossRef citations
  • 0Altmetric
Article
CD8+ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion
Laura Llaó Cid, Bola S. Hanna, Murat Iskar, Philipp M. Roessner, Selcen Öztürk, Peter Lichter, Marc Zapatka & Martina Seiffert
Pages: 351-356
Published online: 13 Sep 2019
AbstractforCD8+ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 766 Views
  • 12 CrossRef citations
  • 0Altmetric
Article
Analysis of the immunity effects after enhanced hepatitis B vaccination on patients with lymphoma
Wei-Huang Zhuang & Ya-Ping Wang
Pages: 357-363
Published online: 15 Oct 2019
AbstractforAnalysis of the immunity effects after enhanced hepatitis B vaccination on patients with lymphoma | Full Text | References | PDF (596.3 KB) | EPUB
  • 1552 Views
  • 4 CrossRef citations
  • 0Altmetric
Open Access
Article
Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody
Kristen M. Sarlo, Brianne N. Dixon, Ai Ni & David J. Straus
Pages: 364-369
Published online: 11 Oct 2019
AbstractforIncidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody | Full Text | References | PDF (952.9 KB) | EPUB
  • 470 Views
  • 9 CrossRef citations
  • 0Altmetric
Article
Risk factors for venous thromboembolism in hospitalized patients with hematological malignancy: an analysis of the National Inpatient Sample, 2011–2015
Veli Bakalov, Amy Tang, Amulya Yellala, Robert Kaplan, John Lister & Santhosh Sadashiv
Pages: 370-376
Published online: 23 Sep 2019
AbstractforRisk factors for venous thromboembolism in hospitalized patients with hematological malignancy: an analysis of the National Inpatient Sample, 2011–2015 | Full Text | References | PDF (722.9 KB) | EPUB | Supplemental
  • 307 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
Heinz Ludwig, Wolfram Pönisch, Stefan Knop, Alexander Egle, Axel Hinke, Martin Schreder, Daniel Lechner, Roman Hajek, Eberhard Gunsilius, Andreas Petzer, Katja Weisel, Dietger Niederwieser, Hermann Einsele, Wolfgang Willenbacher, Holger Rumpold, Ludek Pour, Tomas Jelinek, Karl Jochen Krenosz, Angela Meckl, Sandra Nolte, Thomas Melchardt, Richard Greil & Niklas Zojer
Pages: 377-386
Published online: 26 Sep 2019
AbstractforQuality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population | Full Text | References | PDF (1.6 MB) | EPUB | Supplemental
  • 3252 Views
  • 13 CrossRef citations
  • 0Altmetric
Open Access
Article
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
Bhavana Bhatnagar, Qiuhong Zhao, Alice S. Mims, Sumithira Vasu, Gregory K. Behbehani, Karilyn Larkin, James S. Blachly, William Blum, Rebecca B. Klisovic, Amy S. Ruppert, Shelley Orwick, Christopher Oakes, Parvathi Ranganathan, John C. Byrd, Alison R. Walker & Ramiro Garzon
Pages: 387-396
Published online: 23 Sep 2019
AbstractforSelinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study | Full Text | References | PDF (848.6 KB) | EPUB | Supplemental
  • 532 Views
  • 27 CrossRef citations
  • 0Altmetric
Article
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Amer M. Zeidan, Xin Hu, Weiwei Zhu, Maximilian Stahl, Rong Wang, Scott F. Huntington, Smith Giri, Jan Philipp Bewersdorf, Nikolai A. Podoltsev, Steven D. Gore, Xiaomei Ma & Amy J. Davidoff
Pages: 397-408
Published online: 01 Oct 2019
AbstractforAssociation of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 237 Views
  • 17 CrossRef citations
  • 0Altmetric
Article
Parathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors
Nicole A. Kohart, Said M. Elshafae, Aylin A. Demirer, Wessel P. Dirksen, Justin T. Breitbach, Sherry T. Shu, Jingyu Xiang, Katherine N. Weilbaecher & Thomas J. Rosol
Pages: 409-419
Published online: 08 Oct 2019
AbstractforParathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors | Full Text | References | PDF (2.7 MB) | EPUB
  • 217 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia
Jessica L. Sea, Etan Orgel, Ting Chen, Rebecca L. Paszkiewicz, Abigail S. Krall, Matthew J. Oberley, Linsey Stiles & Steven D. Mittelman
Pages: 420-428
Published online: 16 Sep 2019
AbstractforLevocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia | Full Text | References | PDF (1.4 MB) | EPUB
  • 291 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation
Fei Yang, Xiaodong Yang, Xiebing Bao, Liqing Kang, Lili Zhou, Xiaoxia Wu, Xiaowen Tang, Zhengzheng Fu, Xiao Ma, Aining Sun, Jian Zhang, Huiying Qiu & Deipei Wu
Pages: 429-436
Published online: 12 Sep 2019
AbstractforAnti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation | Full Text | References | PDF (1.1 MB) | EPUB
  • 411 Views
  • 6 CrossRef citations
  • 0Altmetric
Article
Overexpression of SET and MYND domain-containing protein 2 (SMYD2) is associated with poor prognosis in pediatric B lineage acute lymphoblastic leukemia
Ping Zhang, JinFei Ruan, Wenwen Weng & Yongmin Tang
Pages: 437-444
Published online: 15 Oct 2019
AbstractforOverexpression of SET and MYND domain-containing protein 2 (SMYD2) is associated with poor prognosis in pediatric B lineage acute lymphoblastic leukemia | Full Text | References | PDF (1.2 MB) | EPUB
  • 218 Views
  • 7 CrossRef citations
  • 0Altmetric

Letters to the Editor

Letter
First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)
Mansour Alfayez, Beenu Thakral, Preetesh Jain, Farhad Ravandi, Alessandra Ferrajoli, Nitin Jain, Naveen Pemmaraju, William Wierda & Tapan Kadia
Pages: 445-449
Published online: 30 Sep 2019
First Page PreviewforFirst report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL) | Full Text | References | PDF (1.1 MB) | EPUB
  • 892 Views
  • 9 CrossRef citations
  • 0Altmetric
Letter
Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation – diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib
Rashmi Manur, Pamela J. Sung, Alison W. Loren, Ellen K. Ritchie, Dale Frank, Adam Bagg, Julia T. Geyer & Agata M. Bogusz
Pages: 450-454
Published online: 16 Sep 2019
First Page PreviewforLeukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation – diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
  • 469 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter
Selective inhibition of PI3Kγ affects survival and proliferation of chronic lymphocytic leukemia B cells
Rossana Maffei, Stefania Benatti, Claudio Giacinto Atene, Giulia Debbia, Patrizia Zucchini, Leonardo Potenza, Mario Luppi, Stefania Fiorcari & Roberto Marasca
Pages: 455-459
Published online: 14 Nov 2019
First Page PreviewforSelective inhibition of PI3Kγ affects survival and proliferation of chronic lymphocytic leukemia B cells | Full Text | References | PDF (962.7 KB) | EPUB | Supplemental
  • 151 Views
  • 1 CrossRef citations
  • 0Altmetric
Letter
Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications
Priyadarshini Kumar, Manik Uppal, Wenbin Xiao, Ahmet Dogan, Mikhail Roshal, Qi Gao, Umut Aypar, Yanming Zhang, Maria E. Arcila, Christine Moung, Jinjuan Yao, Khedoudja Nafa, Wayne Yu, Mustafa H. Syed, Jae Park, Anita Kumar & Caleb Ho
Pages: 460-464
Published online: 15 Oct 2019
First Page PreviewforClonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications | Full Text | References | PDF (1.2 MB) | EPUB
  • 1926 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Letter
Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia
Rajat Bansal, Joseph G. Jurcic, Ahmed Sawas, Markus Y. Mapara & Ran Reshef
Pages: 465-468
Published online: 22 Sep 2019
First Page PreviewforChimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia | Full Text | References | PDF (630.7 KB) | EPUB
  • 398 Views
  • 12 CrossRef citations
  • 0Altmetric
Letter
Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript
Francesca Fazio, Walter Barberi, Gianni Cazzaniga, Grazia Fazio, Monica Messina, Irene Della Starza, Maria Stefania De Propris, Francesca Mancini, Sara Mohamed, Ilaria Del Giudice, Sabina Chiaretti, Maria Luisa Moleti, Anna Guarini, Robin Foà & Anna Maria Testi
Pages: 469-472
Published online: 27 Sep 2019
First Page PreviewforEfficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript | Full Text | References | PDF (818.3 KB) | EPUB
  • 289 Views
  • 8 CrossRef citations
  • 0Altmetric
Letter
Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors
Laetitia Largeaud, Sarah Bertoli, Emilie Bérard, Stéphanie Dufrechou, Naïs Prade, Noémie Gadaud, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, Audrey Sarry, Véronique De Mas, Françoise Huguet, Eric Delabesse & Christian Récher
Pages: 473-476
Published online: 30 Sep 2019
First Page PreviewforOutcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors | Full Text | References | PDF (569 KB) | EPUB | Supplemental
  • 119 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter
Multiply relapsed mixed histiocytosis in an adult responding to clofarabine after failure of cladribine
Jad Othman, Fiona Bonar, Wendy Brown, Richard Boyle & Teh-Liane Khoo
Pages: 477-480
Published online: 04 Sep 2019
First Page PreviewforMultiply relapsed mixed histiocytosis in an adult responding to clofarabine after failure of cladribine | Full Text | References | PDF (1.2 MB) | EPUB
  • 123 Views
  • 1 CrossRef citations
  • 0Altmetric
Letter
Granulocyte transfusions – bridging to allogeneic hematopoietic stem cell transplantation
Thanh Mai Nguyen, Katrina Scholl, Irina Idler, Verena Wais, Sixten Körper, Ramin Lotfi, Martin Bommer, Markus Wiesneth, Hubert Schrezenmeier, Hartmut Döhner, Stephan R. Bohl, Stephanie von Harsdorf, Peter Reinhardt, Donald Bunjes, Mark Ringhoffer & Florian Kuchenbauer
Pages: 481-484
Published online: 24 Sep 2019
First Page PreviewforGranulocyte transfusions – bridging to allogeneic hematopoietic stem cell transplantation | Full Text | References | PDF (579.8 KB) | EPUB
  • 197 Views
  • 4 CrossRef citations
  • 0Altmetric
Letter
Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide
Ahmet H. Elmaagacli, Christian Jehn, Yana Shikova, Michael Huber, Hans Salwender, Farouk Dahmash, Anju Singh, Cornelius Niggemann & Mathias Vierbuchen
Pages: 485-487
Published online: 30 Sep 2019
First Page PreviewforAdvanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide | Full Text | References | PDF (500.8 KB) | EPUB | Supplemental
  • 268 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter
A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study
Hani Hassoun, Ruthee Bayer, Sean Devlin, Theresa Gentile, Michael Becker, Kristen O’Dweyer, Martin Lesser, Heather Landau, David Chung & Sergio Giralt
Pages: 488-490
Published online: 19 Jan 2020
First Page PreviewforA phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study | Full Text | References | PDF (408.3 KB) | EPUB
  • 201 Views
  • 0 CrossRef citations
  • 0Altmetric
Letter
Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data
Catherine S. Y. Lecat, Caroline Besley, Rachael E. Hough, Asim Khwaja, Caroline Furness, David I. Marks & Adele K. Fielding
Pages: 491-493
Published online: 03 Oct 2019
First Page PreviewforInotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data | Full Text | References | PDF (409.2 KB) | EPUB
  • 336 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter
Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study
Tomáš Horňák, Lukáš Semerád, Daniela Žáčková, Barbora Weinbergerová, Zuzana Šustková, Jiřina Procházková, Petra Bělohlávková, Lukáš Stejskal, Peter Rohoň, Edgar Faber, Pavel Žák, Jiří Mayer & Zdeněk Ráčil
Pages: 494-496
Published online: 03 Oct 2019
First Page PreviewforAnalysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study | Full Text | References | PDF (308 KB) | EPUB
  • 273 Views
  • 3 CrossRef citations
  • 0Altmetric
Letter
Controversies about germline RUNX1 missense variants
Nicolas Duployez & Laurène Fenwarth
Pages: 497-499
Published online: 18 Oct 2019
First Page PreviewforControversies about germline RUNX1 missense variants | Full Text | References | PDF (643.1 KB) | EPUB
  • 278 Views
  • 3 CrossRef citations
  • 0Altmetric

Explore articles